<?xml version='1.0' encoding='utf-8'?>
<document id="10976657"><sentence text="Clinical pharmacokinetics of cerivastatin."><entity charOffset="29-41" id="DDI-PubMed.10976657.s1.e0" text="cerivastatin" /></sentence><sentence text="Cerivastatin sodium, a novel statin, is a synthetic, enantiomerically pure, pyridine derivative that effectively reduces serum cholesterol levels at microgram doses"><entity charOffset="0-19" id="DDI-PubMed.10976657.s2.e0" text="Cerivastatin sodium" /><entity charOffset="76-84" id="DDI-PubMed.10976657.s2.e1" text="pyridine" /><entity charOffset="127-138" id="DDI-PubMed.10976657.s2.e2" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.10976657.s2.e0" e2="DDI-PubMed.10976657.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10976657.s2.e0" e2="DDI-PubMed.10976657.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10976657.s2.e0" e2="DDI-PubMed.10976657.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10976657.s2.e1" e2="DDI-PubMed.10976657.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10976657.s2.e1" e2="DDI-PubMed.10976657.s2.e2" /></sentence><sentence text=" Cerivastatin is readily and completely absorbed from the gastrointestinal tract, with plasma concentrations reaching a peak 2 to 3 hours postadministration followed by a monoexponential decay with an elimination half-life (t1/2beta) of 2 to 3 hours"><entity charOffset="1-13" id="DDI-PubMed.10976657.s3.e0" text="Cerivastatin" /></sentence><sentence text=" Cerivastatin pharmacokinetics are linear: maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) are proportional to the dose over the range of 0"><entity charOffset="1-13" id="DDI-PubMed.10976657.s4.e0" text="Cerivastatin" /></sentence><sentence text="05 to 0" /><sentence text="8 mg" /><sentence text=" No accumulation is observed on repeated administration" /><sentence text=" Cerivastatin interindividual variability is described by coefficients of variation of approximately 30 to 40% for its primary pharmacokinetic parameters AUC, Cmax and t1/2beta"><entity charOffset="1-13" id="DDI-PubMed.10976657.s8.e0" text="Cerivastatin" /></sentence><sentence text=" The mean absolute oral bioavailability of cerivastatin is 60% because of presystemic first-pass effects"><entity charOffset="43-55" id="DDI-PubMed.10976657.s9.e0" text="cerivastatin" /></sentence><sentence text=" Its pharmacokinetics are not influenced by concomitant administration of food nor by the time of day at which the dose is given" /><sentence text=" Age, gender, ethnicity and concurrent disease also have no clinically significant effects" /><sentence text=" Cerivastatin is highly bound to plasma proteins (&gt;99%)"><entity charOffset="1-13" id="DDI-PubMed.10976657.s12.e0" text="Cerivastatin" /></sentence><sentence text=" The volume of distribution at steady state of about 0" /><sentence text="3 L/kg indicates that the drug penetrates only moderately into tissue; conversely, preclinical studies have shown a high affinity for liver tissue, the target site of action" /><sentence text=" Cerivastatin is exclusively cleared via metabolism"><entity charOffset="1-13" id="DDI-PubMed.10976657.s15.e0" text="Cerivastatin" /></sentence><sentence text=" No unchanged drug is excreted" /><sentence text=" Cerivastatin is subject to 2 main oxidative biotransformation reactions: demethylation of the benzylic methyl ether moiety leading to the metabolite M-1 [catalysed by cytochrome P450 (CYP) 2C8 and CYP3A4] and stereoselective hydroxylation of one methyl group of the 6-isopropyl substituent leading to the metabolite M-23 (catalysed by CYP2C8)"><entity charOffset="1-13" id="DDI-PubMed.10976657.s17.e0" text="Cerivastatin" /><entity charOffset="95-116" id="DDI-PubMed.10976657.s17.e1" text="benzylic methyl ether" /><entity charOffset="247-253" id="DDI-PubMed.10976657.s17.e2" text="methyl" /><entity charOffset="267-278" id="DDI-PubMed.10976657.s17.e3" text="6-isopropyl" /><pair ddi="false" e1="DDI-PubMed.10976657.s17.e0" e2="DDI-PubMed.10976657.s17.e0" /><pair ddi="false" e1="DDI-PubMed.10976657.s17.e0" e2="DDI-PubMed.10976657.s17.e1" /><pair ddi="false" e1="DDI-PubMed.10976657.s17.e0" e2="DDI-PubMed.10976657.s17.e2" /><pair ddi="false" e1="DDI-PubMed.10976657.s17.e0" e2="DDI-PubMed.10976657.s17.e3" /><pair ddi="false" e1="DDI-PubMed.10976657.s17.e1" e2="DDI-PubMed.10976657.s17.e1" /><pair ddi="false" e1="DDI-PubMed.10976657.s17.e1" e2="DDI-PubMed.10976657.s17.e2" /><pair ddi="false" e1="DDI-PubMed.10976657.s17.e1" e2="DDI-PubMed.10976657.s17.e3" /><pair ddi="false" e1="DDI-PubMed.10976657.s17.e2" e2="DDI-PubMed.10976657.s17.e2" /><pair ddi="false" e1="DDI-PubMed.10976657.s17.e2" e2="DDI-PubMed.10976657.s17.e3" /></sentence><sentence text=" The product of the combined biotransformation reactions is a secondary minor metabolite, M-24, not detectable in plasma" /><sentence text=" All 3 metabolites are active inhibitors of hydroxymethylglutaryl-coenzyme A reductase with a similar potency to the parent drug" /><sentence text=" Approximately 70% of the administered dose is excreted as metabolites in the faeces, and 30% in the urine" /><sentence text=" Metabolism by 2 distinct CYP isoforms renders cerivastatin relatively resistant to interactions arising from inhibition of CYP"><entity charOffset="47-59" id="DDI-PubMed.10976657.s21.e0" text="cerivastatin" /></sentence><sentence text=" If one of the pathways is blocked, cerivastatin can be effectively metabolised by the alternative route"><entity charOffset="36-48" id="DDI-PubMed.10976657.s22.e0" text="cerivastatin" /></sentence><sentence text=" In addition, on the basis of in vitro investigations, there is no evidence for either cerivastatin or its metabolites having any inducing or inhibitory activity on CYP"><entity charOffset="87-99" id="DDI-PubMed.10976657.s23.e0" text="cerivastatin" /></sentence><sentence text=" The apparent lack of any clinically relevant interactions with a variety of drugs commonly used by patients in the target population supports this favourable drug-drug interaction profile" /><sentence text="" /></document>